IDEXX LABORATORIES INC /DE is 25.4x more valuable than Intellia Therapeutics, Inc. by market capitalization ($43.93 B vs $1.73 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IDXX | NTLA |
|---|---|---|
| Market cap | $43.93 B | $1.73 B |
| US-listed rank | #351 | #2213 |
| Revenue (latest FY) | $4.30B | $67.67M |
| Net income (latest FY) | $1.06B | -$412.69M |
| Net margin | 24.6% | -609.9% |
| P/E (trailing FY) | 41.5 | - |
| SEC filings | 2,148 | 687 |
IDEXX LABORATORIES INC /DE is 25.4x more valuable than Intellia Therapeutics, Inc. by market capitalization ($43.93 B vs $1.73 B).
In their latest fiscal years, IDEXX LABORATORIES INC /DE reported $4.30B in revenue while Intellia Therapeutics, Inc. reported $67.67M.
Full pages: IDEXX LABORATORIES INC /DE and Intellia Therapeutics, Inc., or browse the full rankings.